From: Advances in technology and applications of nanoimmunotherapy for cancer
Compound name | NP formulation | NP payloads | Mechanisms of immunotherapy | Anti-tumor immunological effect | Clinical trials | Reference |
---|---|---|---|---|---|---|
RNA-LPX | Lipoplexes | RNA encoding mutant neo-antigens | NP-based tumor RNA delivery | Systemic DC targeting; Adaptive T cell response | Phase I | [137] |
JVRS-100 | Cationic liposome | Plasmid DNA Complex | NP-based tumor DNA delivery | Anti-tumor immune stimulation | Phase I | |
Anti-EGFR-IL-dox | Liposome | Doxorubicin-loaded anti-EGFR | NP mediated ICD | Immunological cell death induction | Phase II | |
PTX-LDE | Lipid NPs | Paclitaxel | NP mediated ICD | Immunological cell death induction; DC maturation | Phase II | [138] |
NBTXR3 | Hafnium oxide NPs | Anti-PD1 | NP mediated ICD | Immunological cell death induction | Phase I | |
Ferumoxytol | Iron oxide NPs | Nil | NP mediated remodeling of TIM | Polarizing M2 to M1 | FDA approved for anemia and kidney disease | [89] |